2月3日 - ** 摩根大通首次覆盖阿克蒂斯肿瘤公司AKTS.O，并给予"增持"评级，将目标价定为30美元。
** 券商称赞癌症药物开发商开发放射性药物疗法的平台，这种疗法是一种新型的癌症靶向放射治疗手段
** 摩根大通表示："我们认为放射治疗模式将在未来几年内兴起，Aktis的进入正处于一个甜蜜点，既能利用过去在该领域的经验，又能尽早定位，在一个相对开放的领域开发一流的产品。"
** 包括本交易日的走势在内，AKTS 自 1 月 9 日上市以来下跌了 20.9%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.